Abstract
Genomic biomarkers will help to elucidate which cancer patients will benefit from PD-1 blockade immunotherapy.
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have